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Abstract: Diabetes mellitus (DM) has become an increasingly common disease with high disability and
mortality rates. Diabetes complications are the main cause of diabetes death and about 50% of diabetic
patients died from heart disease in developed countries reported by World Health Organization. Diabetic
cardiomyopathy (DCM) has been considered as a high incidence and serious complication of DM and plays
a key role in the incidence and development of diabetes related heart failure. Metabolism dysregulation
is regarded as an important and earlier factor occurred in the pathogenesis of DCM. Insulin resistance,
oxidative stress, inflammation and mitochondrial dysfunction also contribute to the development of DCM.
Farnesoid X Receptor (FXR) is a member of nuclear receptor superfamily, and plays a critical role in
regulating lipid and glucose metabolism, oxidative stress and inflammation. FXR is activated by primary
bile acids (BAs) such as chenodeoxycholic acid, cholic acid and synthetic agonists such as obeticholic acid.
BAs are the main active ingredients of many natural products and traditional medicines, especially bile
or gallstones in animals, such as calculus bovis. Due to the regulatory effect of FXR on glucose and lipid
metabolism, oxidative stress and inflammation, the treatment of BAs and FXR agonists for metabolic
syndrome and DCM have gained more attention. This review will focus on the pathogenesis of diabetic
cardiomyopathy and the regulatory effect of BAs and FXR on DCM.
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Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of 
Diabetic Cardiomyopathy 
 
Abstract: Diabetes mellitus (DM) has become an increasingly common disease with high disability and mortality rates. 
Diabetes complications are the main cause of diabetes death and about 50% of diabetic patients died from heart disease in 
developed countries reported by World Health Organization. Diabetic cardiomyopathy (DCM) has been considered as a 
high incidence and serious complication of DM and plays a key role in the incidence and development of diabetes related 
heart failure. Metabolism dysregulation is regarded as an important and earlier factor occurred in the pathogenesis of 
DCM. Insulin resistance, oxidative stress, inflammation and mitochondrial dysfunction also contribute to the development 
of DCM. Farnesoid X Receptor (FXR) is a member of nuclear receptor superfamily, and plays a critical role in regulating 
lipid and glucose metabolism, oxidative stress and inflammation. FXR is activated by primary bile acids (BAs) such as 
chenodeoxycholic acid, cholic acid and synthetic agonists such as obeticholic acid. BAs are the main active ingredients of 
many natural products and traditional medicines, especially bile or gallstones in animals, such as calculus bovis. Due to 
the regulatory effect of FXR on glucose and lipid metabolism, oxidative stress and inflammation, the treatment of BAs 
and FXR agonists for metabolic syndrome and DCM have gained more attention. This review will focus on the 
pathogenesis of diabetic cardiomyopathy and the regulatory effect of BAs and FXR on DCM.  
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1. INTRODUCTION 
Diabetes mellitus (DM) has become a global health 
problem and the prevalence of diabetes has been increasing 
at a fast speed owing to changes of dietary and the sedentary 
lifestyle. It was estimated that 451 million people (8.4% of 
the world population) lived with diabetes in 2017 and the 
number was predicted to rise to 693 million by 2045 [1]. 
People with diabetes have a much higher risk of developing 
cardiovascular complications. Diabetic cardiovascular 
disease has been considered as the major cause of diabetes 
mortality, and about 50% of diabetic patients died from heart 
disease in developed countries reported by the World Health 
Organization [2]. Diabetic cardiomyopathy (DCM) is a high 
incidence and serious complication of diabetes and often 
evolves to diabetes related heart failure. DCM was first 
described by Rubler [3] in 1972 and further confirmed by the 
well-known Framingham study in 1974 which showed a four 
to five fold increased risk of congestive heart failure in 
diabetic patients even after excluding coronary or rheumatic 
heart disease [4]. DCM is characterized by the abnormal 
myocardial structural and cardiac dysfunction in the absence 
of hypertension, coronary artery disease and other cardiac 
risk factors [5]. The pathogenesis of DCM is complex and 
multifactorial, including altered substrate metabolism, 
oxidative stress, inflammation, insulin resistance and 
mitochondrial dysfunction [5, 6]. Microvascular dysfunction 
[7, 8], altered calcium handling [9] and accumulation of 
advanced glycation end-products [10] also implicated in 
different stages of DCM resulting in cardiac dysfunction, 
fibrosis and cell signaling abnormalities.   
Bile acids (BAs) are the main active ingredients of many 
natural products, especially bile or gallstones in animals, 
which are widely used in traditional medicine. For example, 
calculus bovis (bovine gallstones) is commonly used to 
reduce inflammation and to treat cardiovascular diseases in 
traditional medicine. Besides natural BAs, some synthetic 
medicine are also applied to many diseases, for instance, the 
synthesized ursodeoxycholic acid is used in the treatment of 
diverse hepatobiliary disorders, including cholestatic liver 
disease and steroidal gallstone. Certain BAs also play the 
role in modulating molecular signaling pathways and 
substrate metabolism by activating farnesoid X receptor 
(FXR). Due to the regulatory effect of FXR on inflammation, 
mitochondrial dysfunction and oxidative stress, the treatment 
with BAs and FXR agonists for metabolic syndrome and 
DCM have gained more attention. This review will focus on 
the role of inflammation, mitochondrial dysfunction and 
oxidative stress in the pathogenesis of DCM and the 
regulatory effect of BAs and FXR.    
2. BAs METABOLISM AND FXR 
 Primary BAs are synthesized by cholesterol within the 
liver and conjugated with taurine and glycine. Primary BAs 
are conjugated with the amino acids taurine or glycine before 
they are secreted into the bile canalicular. Conjugation of 
BAs is conductive to increase the BAs hydrophilicity and 
decrease the lipid toxicity. BAs are stored in the gallbladder 
and secreted into the intestine after a meal. Primary BAs are 
subjected to a series of structural modifications and 
metabolized to secondary BAs by bacterial enzymes [11]. 
Following this step, a variety of primary BAs and secondary 
BAs make up the bile acid pool which is necessary for the 
lipid solubilization and absorption in the enterohepatic cycle. 
About 95% of the bile acid pool are reabsorbed from 
intestine return to liver through the enterohepatic cycle. The 
remaining 5% of the pool are excreted in the feces and 
replaced by de novo synthesis [12]. 
FXR is a member of nuclear receptor superfamily which is 
described by Forman in 1995 [13]. FXR was found to be 
activated by primary BAs such as chenodeoxycholic acid 
(CDCA), cholic acid (CA) and synthetic agonists such as 
obeticholic acid (OCA) [14] and then plays a critical role in 
regulating lipid metabolism, glucose metabolism, oxidative 
stress and inflammation [15, 16]. After activation, FXR 
binds to FXR response elements (FXREs) or forms 
heterodimers with the 9-cis-retinoic acid receptor (RXR), 
regulating the transcription of target genes involved in BAs 
synthesis, conjugation, absorption and secretion [16, 17]. 
FXR can also activate the small heterodimer partner (SHP) 
to inhibit the expression of liver receptor homolog, liver X 
receptor, and then resulting in inhibiting the transcription of 
cholesterol 7a-hydroxylase (CYP7A1), which is the 
rate-limiting enzyme of bile acid synthesis and cholesterol 
metabolism [18, 19]. Moreover, BAs is closely related to the 
homeostasis of triglycerides as the interruption of the 
enterohepatic circulation of bile acids result in elevated 
plasma triglyceride levels. It has demonstrated that FXR 
activated SHP to regulate fatty acids and triglycerides 
biosynthesis via inhibiting the expression of Acetyl-CoA 
Synthetase (AceCs), Malic Enzyme (ME) and Stearoyl-CoA 
Desaturase-1 (Scd-1) [11]. 
FXR is wildly expressed in several tissues, such as liver, 
intestines, kidney and adrenals. Recent studies have 
demonstrated that FXR is also expressed in adult 
cardiomyocytes, heart tissues and different cell types of the 
vascular wall [20, 21]. Except the effect on control of bile 
acid synthesis and cholesterol metabolism, FXR is also 
involved in various physiological and pathological processes 
of cardiovascular diseases, including inflammatory response, 
oxidative stress, apoptosis and vascular remodeling. Recently, 
numerous studies have demonstrated the role of FXR in 
cardiovascular system [22, 23]. It has been reported that 
activation of FXR boosted reverse cholesterol transport 
through inhibiting hepatic CYP7A1 and prevented the 
development of atherosclerosis [23]. Moreover, FXR ligand 
has been found to play a positive role in reducing 
cardiomyocytes apoptosis, fibrosis and restoring heart 
insulin signaling [24]. Conclusively, FXR has been 
considered as a novel key-target for the treatment of 
cardiovascular diseases including cardiomyopathy and 
atherosclerosis.    
3. INFLAMMATION AND DCM 
3.1 Role of Inflammation in the Pathogenesis of DCM 
Both clinic study and animal models have demonstrated 
that an increased inflammation was involved in the 
pathologic process of DCM [25-27]. Increased expression of 
proinflammatory cytokines, such as, intercellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1), tumor necrosis factor (TNF-α), IL-6 and IL-1β 
contribute to inflammatory injury, myocardial remodeling 
and cardiac diastolic dysfunction, and nuclear factor 
(NF)-κB is responsible for the expression or activation of 
proinflammatory cytokines [6, 5, 28]. Mouse or rat models 
of DM have demonstrated that inhibition expression of 
proinflammatory cytokines attenuated left ventricular 
dysfunction and cardiac fibrosis [28, 29]. On the other hand, 
it have been shown that the anti-inflammatory treatments or 
interventions not only decreased the inflammatory injury, but 
also attenuated oxidative stress, remodeling and cardiac 
dysfunction in DCM [30, 31]. 
Angiotensin-1 (AT-1) receptor, p38 mitogen-activated 
protein kinase (MAPK) signaling pathway, NOD-like 
receptor pyrindomain-containing-3 (NLRP3) inflammasome 
and oxidative stress induced by ROS have been recognized 
as the major contributors of inflammatory response in DCM 
(Fig. 1) [6, 32, 33]. Irbesartan, an AT-1 receptor antagonist, 
was reported to reduce the level of proinflammatory 
cytokines (TNF-α, TGF-β and IL-1β) and attenuate cardiac 
fibrosis in STZ-induced diabetic mice [33]. TNF-α activates 
p38 MAPK signaling pathway, which then mediates 
inflammatory damage and cell apoptosis in DCM [34]. 
Inhibition of p38 MAPK attenuated the left ventricular 
dysfunction through decreasing the expression of 
proinflammatory cytokines in DCM mouse models [35]. 
Increasing evidence reveals that NLRP3 inflammasome 
might be a novel molecular marker in DCM [5, 36]. It is also 
known, that NLRP3 inflammasome expressed abundantly in 
cardiomyocytes, played a critical role in cell death [36]. 
Recent studies have indicated that the expression of NLRP3 
inflammasome was increased under conditions of 
hyperglycemia and lipid accumulation in DM and obesity 
[37, 38]. Furthermore, NF-κB was found to involve in the 
transcriptional induction and activation of the NLRP3 
inflammasome [39, 40]. One of NLRP3 inflammasome 
function is to process pro-IL-18 and pro-IL-1β into the 
mature forms (IL-18 and IL-1β), which are considered as the 
main risk factors of myocardial inflammatory injury and 
cardiomyocytes apoptosis in DCM [35]. Activation of 
NLRP3 inflammasome results in caspase-1 processing and 
activation, which cleaves gasdermin D into two fragments 
and induces the lytic pro-inflammation cell death known as 
pyroptosis [41, 42]. A complex relationship exists between 
oxidative stress and inflammation, in which increased ROS 
production resulted in the increased expression of 
inflammatory cytokines, and conversely, high level of 
inflammatory cytokines can promote the production of ROS 
[32]. ROS generation induced by hyperglycemia could 
activate NF-κB and thioredoxin interacting/inhibiting protein 
(TXNIP), which account for the increased NLRP3 
inflammasome expression in DCM [43, 44]. 
 
3.2 The effect of BAs and FXR on inflammation 
A recent experimental study has revealed that FXR-/- mice 
had a higher TNF-α mRNA level compared with wide-type 
mice fed the same chow diet [45]. Besides that, FXR-/- mice 
fed high fat diet had a dramatic increased TNF-α level 
Fig. (1). Inflammation is involved in the pathologic process of DCM. 
Under the hyperglycemia and insulin resistance condition in diabetes, 
activation of angiotensin-1 (AT-1) receptor and p38 MAPK signaling 
pathway, increased of NOD-like receptor pyrindomain-containing-3 
(NLRP3) inflammasome and oxidative stress induce the expression of 
proinflammatory cytokines, resulting in inflammatory response in DCM. 
 
compared with wide-type mice fed normal diet [45]. These 
findings showed that loss of functional FXR results in 
increased inflammation. On the other hand, it has also been 
reported that both natural and synthetic FXR ligands 
inhibited the production of IL-1β, IL-6, and TNF-α from 
macrophage in response to LPS-induced Toll-like receptor 
(TLR-4) activation, but that is not the case in FXR-/- mice 
[46]. Moreover, FXR activation showed a vital role in 
regulating cardiovascular inflammatory response. There is no 
doubt that NF-κB is considered an important regulator of the 
inflammatory response. Activated NF-κB enters the nucleus 
and binds to DNA, thereby inducing the transcription of 
TNF-α, IL-6, inducible nitric oxide synthase (iNOS) and 
cyclooxygenase (COX)-2. The inhibitory effect of FXR 
activation on hepatic inflammation via suppressing NF-κB 
signaling has been confirmed [47]. Recent study has 
demonstrated that activation of FXR and SHP in vascular 
smooth muscle cells (VSMC) suppressed IL-1β-induced 
NF-κB activation and reduced the expression of iNOS and 
COX-2 which contributed to vascular inflammation, VSMC 
migration and atherosclerosis lesions [22]. FXR agonist 
CDCA treatment decreased the blood pressure through 
increasing eNOS and NO production and reducing 
endothelin-1 (ET-1) expression [48]. In addition, FXR 
activation inhibited the inflammatory response through 
suppressing the activation of NF-κB and expression of 
VCAM-1 [48]. To summarize, these data suggest that FXR 
ligands (BAs) play a potential role in attenuating 
inflammation in cardiovascular diseases such as 
atherosclerosis and cardiomyopathy. 
4. MITOCHONDRIAL DYSFUNCTION AND DCM 
4.1 Role of Mitochondrial Dysfunction in the 
Pathogenesis of DCM 
It is well known that about 90% of intracellular ATP is 
provided by mitochondrial oxidative phosphorylation in 
cardiomyocytes [9], thus mitochondrial dysfunction plays a 
critical role in the development of cardiomyopathy. Though 
less studies provided direct evidence for mitochondrial 
dysfunction in diabetic patients, a number of animal models 
has directly demonstrated that cardiac mitochondrial 
dysfunction is a major risk factor for myocardial damage, 
remodeling and the development of DCM [49]. Interestingly, 
myocardial contractile dysfunction was associated with 
mitochondrial dysfunction in type 2 diabetic patients but not 
in obese patients who were only in the early stage of insulin 
resistant [50]. This means that mitochondrial dysfunction 
rather than insulin resistant might be the main culprit factor 
of DCM. Increased mitochondrial number has been found in 
diabetic cardiomyocytes, suggesting a compensative 
response to overcome impaired mitochondrial function [51, 
52]. 
Glucose and free fatty acid (FFA) are the two major 
energy production sources for cardiomyocytes. However, 
FFA oxidation turn to the major source of ATP production 
due to the insulin resistance and hyperglycemia in DM, 
accompanied by impaired mitochondrial oxidative 
phosphorylation and increased ROS generation [5, 9, 53]. 
Physiologically, complexes I and III in the electron transport 
chain are the major place for the production of mitochondrial 
ROS. Under hyperglycemia and insulin resistance conditions, 
increased flux of electron transfer donors to the 
mitochondrial respiratory chain results in hyperpolarization 
of the mitochondrial inner membrane, and then inhibits 
electron transport in complex III which lead to an excess 
generation of ROS [54]. Mitochondrial ROS conversely 
impaired the mitochondrial function, since mitochondrial 
DNA is more sensitive to oxidative damage induced by ROS 
[54].  
Impaired Ca2+ handling is also a vital promoter of the 
mitochondrial respiratory dysfunction. Calcium plays a 
critical role in regulating the activation of metabolic 
enzymes and the production of ATP, as well as impaired 
mitochondrial Ca2+ uptake and handling in cardiomyocytes 
was reported in DM [55, 56]. Some studies have shown that 
mitochondria in diabetic cardiomyocytes are sensitive to 
mitochondrial permeability transition pores (mPTP) opening, 
which could be induced by impaired mitochondrial Ca2+ 
handling, resulting in cardiomyocytes necrosis [57]. In 
addition, mitochondrial function is closely related with 
mitochondrial biogenesis. Peroxisome proliferator-activated 
receptor-gamma coactivator (PGC)-1α served as an 
important role in mitochondrial biogenesis, calcium 
signaling and regulation of respiratory activity [58]. Recent 
study has reported that PGC-1α was involved in 
mitochondrial dysfunction in DCM, since PGC-1α is known 
to mediate the mitochondrial number and the expression of 
PGC-1α is decreased at later stages of diabetes [49, 59]. 
4.2 The effect of BAs and FXR on mitochondrial 
dysfunction 
FXR is a critical regulator of glucose and lipid metabolism 
which are closely linked to mitochondrial function. Previous 
study has demonstrated that FXR activation reduced the 
mitochondrial dysfunction and oxidative stress, which 
thereby inhibited the hepatic fibrosis [60]. Emerging study 
has shown that FXR agonist CDCA treatment in 
cardiomyocytes upregulated some genes involved in 
β-oxidation and mitochondrial function such as 
malonyl-CoA decarboxylase (MCD), AOX, PDK-4 and 
uncoupling protein (UCP)-3 [24]. However, a recent study 
has reported that FXR activation promoted mPTP opening, 
cytochrome c release, and reduced mitochondrial membrane 
potential, which thereby induced the mitochondrial 
dysfunction and cardiomyocytes apoptosis [20]. Conversely, 
our recent data have indicated that FXR activation protected 
against myocardial damage induced by hyperlipidemia or 
palmitic acid, which was also consistent with another study 
[24]. In addition, it was reported that FXR activation rescued 
the post-myocardial infarction cardiac dysfunction and 
remodeling via increased mitochondrial biogenesis and 
reduced myocardial inflammation [61]. The further 
mechanism study has shown that FXR activation increased 
atrial natriuretic peptide (ANP) expression and secretion, 
which increased phosphorylation of AMPK and expression 
of PGC-1α in cardiomyocytes [57]. 
Autophagy is a dynamic and highly conserved cellular 
catabolic process that degrades damaged organelles and 
proteins to keep cellular homeostasis [62]. Increased 
evidences have demonstrated that autophagy is closely 
linked to the mitochondrial function, especially the 
mitophagy [63]. It was reported that CREB is a novel 
transcriptional activator of autophagy and FXR activation 
may inhibit the CREB activity, resulting in suppressing 
hepatic autophagy after feeding [64]. However, one other 
study has shown that FXR deficiency reduced the activation 
of forkhead Box O3a which was induced by ethanol, and 
then repressed the autophagy process [65]. To summarize, 
FXR shows a critical regulatory effect on autophagy and 
mitochondrial function.  
5. OXIDATIVE STRESS AND DCM 
5.1 Role of Oxidative Stress in the Pathogenesis of DCM 
  Oxidative stress has been regarded as the main criminals 
in the onset of DM and DCM. It was demonstrated that 
oxidative damage induced by reactive oxygen or nitrogen 
species (ROS or RNS) of myocardium played a critical role 
in the early pathologic alterations of DCM [28, 66, 67]. 
Oxidative modification of DNA, protein and lipid by excess 
ROS is closely associated with some potentially harmful 
aberrations including protein degradation, local or global 
unfolding and dissociation of catalytic subunits of enzymes 
in DCM [28]. In addition, a state of hyperglycemia or 
fluctuating blood glucose levels can induce acute oxidative 
stress that might be the key factor for the early pathologic 
alterations of DCM [68]. Increased oxidative stress in 
diabetes is also involved in cardiomyocytes inflammation, 
apoptosis and myocardial dysfunction even diabetic heart 
failure.   
Impaired glucose uptake and inappropriate glycogenolysis 
and gluconeogenesis increase plasma glucose levels 
promoting the ROS synthesis, thus hyperglycemia is 
considered as the major promoter for the synthesis of ROS in 
the diabetic heart, and advanced glycation end-products 
(AGEs), nicotinamide adenine dinucleotide phosphate 
(NAPDH) oxidase, xanthine oxidase (XO), uncoupling of 
nitric oxide synthase (NOS), lipoxygenase enzymes and 
mitochondrial electron transport chain (ETC) have also been 
reported to contribute to generate ROS (Fig. 2) [69, 70]. As a 
major intracellular source of ATP synthesis, mitochondria 
generate excessive ROS as a result of promoting oxidative 
metabolic flux under conditions of hyperglycemia. In 
another case, saturated ETC in hyperglycemia will force 
electrons to be transfered to molecular oxygen and form 
superoxide within mitochondria, since the ability of ETC to 
transfer electrons depends on intracellular glucose 
concentration [71]. The hyperglycemic state in diabetes 
induces citric acid cycle hyperactivity to promote the glucose 
metabolism, which inevitably generate excessive superoxide 
at complex I and complex III in ETC70. Excessive 
superoxide also induces ETC uncoupling resulting in 
swelling of the mitochondrial matrix and further superoxide 
generation to produce oxidative stress [72].  
Recent studies have demonstrated that NAPDH oxidases 
are responsible for large amounts of ROS generation by 
non-mitochondrial source. Activity or expression of NAPDH 
oxidases in the diabetic heart has been reported to be 
significantly higher [73-75]. It was reported that superoxide 
production was significantly reduced in cardiac-specific 
NOX4 knockout mice, indicating that NOX4 was a major 
source of the generation of superoxide [76]. In addition, 
hyperglycemia-induced NAPDH oxidases activation 
produces superoxide which can combine with nitric oxide 
(NO), producing more harmful peroxynitrite species [67]. 
The specific role of XO in the pathogenesis of DCM is not 
well clear, but inhibition of XO significantly decreased 
myocardial ROS generation and iNOS expression, 
attenuating the cardiomyocytes apoptosis and fibrosis in type 
I diabetic mouse [77]. Uncoupling of NOS leads to increased 
ROS generation and decreased NO bioavailability since 
uncoupled NOS produces more superoxide anion instead of 
NO. Therefore, the uncoupling of NOS increases oxidative 
stress and is implicated in the pathological changes of DCM. 
Lipoxygenases are a family of enzymes that oxidatively 
metabolise arachidonic acid into hydroperoxides. 12/15 
lipoxygenases are closely related with ROS production. It 
has been reported that activation of 12/15 lipoxygenases 
resulted in increased oxidative stress and promoting the 




5.2 The Effect of BAs and FXR on Oxidative Stress 
Recent studies have shown that FXR plays a positive role 
in suppressing oxidative stress. Jun Pu et al. has reported that 
the expression of FXR and SHP in neonatal rat ventricular 
myocytes exposed to H2O2 significantly increased, 
indicating myocytes exhibit a response to ROS with an 
activation in FXR [20]. Another study showed that activation 
of FXR by CDCA in rat heart upregulated the expression of 
some genes involved in β-oxidation such as acyl-CoA 
oxidase and pyruvate dehydrogenase kinase. Moreover, FXR 
activation also reduced lipid content, attenuated the 
cardiomyocytes apoptosis and restored heart insulin 
signaling [24]. It is well known that the bioactivity of NOS 
and NO are closely related to the ROS production. Recent 
works have demonstrated that activation of FXR in vascular 
endothelial cells increased the expression of endothelial 
NOS and NO, which indicated the regulatory effect of FXR 
activation on endothelial oxidative stress [78]. In addition, 
our group and others demonstrated that activation of FXR 
attenuated oxidative stress characterized by the increased 
level of superoxide dismutase (SOD) and glutathione 
peroxidase (GSH-Px), decreased level of malondialdehyde 
(MDA) and ROS in both mouse liver and kidney [79, 80]. 
Further study has demonstrated that the regulatory effect of 
FXR on oxidative stress might be related to the 
phosphorylation of AMP-activated protein kinase (AMPK) 
and the activation of nuclear erythroid factor 2-related factor 
2 (Nrf2) [81]. Nrf2 has been found to mediate in the 
inhibitory effect of FXR on cellular oxidative stress [79, 82, 
83]. FXR activation increased AMPK phosphorylation and 
Nrf2 expression, resulting in decreased ROS level and 
increased levels of SOD and GSH-Px [77]. Nrf2 acts a key 
role in regulating intracellular redox homeostasis via 
enhancing antioxidant capacity and reducing ROS-induced 
damage [84, 85]. Furthermore, Nrf2 also can translocate 
from cytosol to nucleus resulting in activating the phase II 
antioxidants such as heme oxygenase-1 (HO-1) and 
glutathione S-transferase (GST), which also protect cells 
from ROS [86].  
CONCLUSION 
  The features of DCM are characterized by cardiomyocytes 
apoptosis, myocardial fibrosis, remodeling and cardiac 
dysfunction. Hyperglycemia and insulin resistance serve as 
the pivotal factors in the pathogenesis of DCM, which also 
involved oxidative stress, inflammation and mitochondrial 
dysfunction. There is no doubt that the pathogenesis of DCM 
is multifactorial, eventually resulting in cardiac dysfunction 
and heart failure. BAs, synthesizing from cholesterol in the 
hepatocyte, binds FXR to conversely regulate the synthesis 
and metabolism of BAs. In addition, FXR activation also 
participates in the pathological of many diseases, such as 
alcoholic liver disease, nonalcoholic fatty liver disease, 
cardiovascular diseases and carcinogenesis. Increased 
evidences have demonstrated that BAs and FXR play a vital 
role in regulating lipid metabolism, glucose metabolism, 
Fig. (2). Oxidative stress induced by ROS plays a critical role in the pathologic alterations of DCM. Under the hyperglycemia condition, 
advanced glycation end-products (AGEs), nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase, xanthine oxidase (XO), uncoupling of 
nitric oxide synthase (NOS), lipoxygenase enzymes and mitochondrial electron transport chain (ETC) contribute to generate excessive ROS. 
Oxidative modification of DNA, protein and lipid by excess ROS result in cardiomyocytes inflammation, apoptosis and myocardial dysfunction. 
oxidative stress, inflammation and mitochondrial function, 
showing a potential therapeutic effect for DCM. However, 
further studies are essential to reveal the precise mechanisms 
of FXR in DCM treatment and to explore novel therapeutic 
strategies. 
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